AQ4N for Advanced Malignancies Resistant to Standard Chemotherapy

This study focuses on individuals with advanced cancers that have not responded to standard chemotherapy or for which no reliable treatments exist. The study aims to test an experimental chemotherapy drug called AQ4N. This drug is unique as it targets areas of the tumor with low oxygen and poor blood supply, areas that are typically resistant to standard chemotherapy and radiation treatments. The potential benefit of AQ4N is that it may interfere with a protein necessary for cell growth and division, potentially causing tumors to die or slow their growth. All participants in this study will receive AQ4N via intravenous administration. The dose will be gradually increased for each new patient or group of patients. This continuation will occur until the maximum tolerated dose is identified. The study measures the results by evaluating how well the participants tolerate the increasing doses of AQ4N.